Ben [Analyst]'s questions to Protalix Biotherapeutics Inc (PLX) leadership • Q1 2025
Question
Ben [Analyst] from Pareto Securities asked if the upcoming Phase II trial for the gout candidate PRX-115 would enroll U.S. patients and what potential advantages PRX-115 might have over KRYSTEXXA beyond a different injection frequency.
Answer
Executive Dror Bashan confirmed that the majority of patients for the PRX-115 Phase II trial will indeed be enrolled in the U.S. He added that while a less frequent dosing schedule is a significant advantage, the company also hopes to demonstrate a superior immunogenicity and safety profile, but emphasized that this will need to be confirmed by the trial's results.